Females have a higher risk for autoimmune disease and lower risk of mortality from infectious disease than males, reflecting a more robust immune response in females against both self-antigens (autoimmunity) and non-self-antigens...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SEXimmune
Deciphering sex differences in the human immune system
1M€
Cerrado
XCYCLE
Toward a comprehensive analysis of the dynamics and mechanis...
2M€
Cerrado
PID2021-125277OB-I00
DESCIFRANDO EL PAPEL Y LA REGULACION DE LA ARQUITECTURA DEL...
303K€
Cerrado
EPIGENETIX
Epigenetic regulation and monoallelic gene expression the X...
3M€
Cerrado
REGVARMHC
Genetic and epigenetic determinants of allele specific gene...
1M€
Cerrado
IMMUNO
Immunogenomics Mouse to Human Translational Research
1M€
Cerrado
Información proyecto XX-Health
Duración del proyecto: 60 meses
Fecha Inicio: 2022-10-10
Fecha Fin: 2027-10-31
Líder del proyecto
LINKOPINGS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Females have a higher risk for autoimmune disease and lower risk of mortality from infectious disease than males, reflecting a more robust immune response in females against both self-antigens (autoimmunity) and non-self-antigens (infections). Genes that escape the process of X-inactivation (XCI) are present in a higher dose in female cells and many play key roles in T-cell biology. XX-Health will reveal the role of escape genes in mediating sex-differences in T-cell response.
Different cells in a tissue can inactivate the maternal (Xm) or paternal X-chromosome (Xp) (mosaicism). In addition, different ratios of Xm and Xp may become silenced in cells of a given tissue resulting in skewed X-inactivation (sXCI), rendering functional dissection of XCI very challenging. Rare females (~1:300) inactivate the same parental X-chromosome in all cells (cXCI), removing the confounding effect of mosaicism, and offering a powerful genetic system in which to dissect XCI in T-cell biology.
We will develop a novel methodology, TriX-Seq, allowing high-resolution screening of sXCI and cXCI in a large (N~8,000) unselected cohort of females. Using T-cells isolated from identified cXCI females, we will (i) generate a unique multi-omic map of XCI during human T-cell differentiation at a resolution well beyond the state-of-the-art and (ii), directly test the function of alleles specifically expressed from the inactive X-chromosome (Xi) in T-cell biology. With sXCI data in hand, we will also reveal the associations, if any, of sXCI with disease risk and use the unique availability of parental and grand-parental DNA to assess the genetic origin of cXCI.
Sex-bias in COVID-19 mortality has highlighted the importance of sex as a contributor to disease risk. The technical and conceptual advances delivered by XX-Health will make a seminal contribution to our understanding of this poorly understood component of human health.